Vitamin E Slows Decline in Patients With Mild Alzheimer’s

Vitamin E Slows Decline in Patients With Mild Alzheimer’s

Vitamin E can help slow the effects of mild to moderate forms of Alzheimer’s disease, a finding doctors should consider for treating patients, researchers said. Patients given high doses of vitamin E for about two years delayed progression of the degenerative brain disease by about 6.2 months, compared with those given a placebo, according to a study published today in the Journal of the American Medical Association. Doctors may want to discuss vitamin E as an option in early-stage Alzheimer’s treatments, the researchers said.Vitamin E acts like an antioxidant, which may prevent or delay cell damage, and boost the immune system. The new study builds on findings that showed vitamin E seemed to slow disease progression in patients with moderately severe Alzheimer’s and is the first to show it may help stall functional decline in those with milder forms, said Maurice Dysken, the lead author.

“A delay in six months over two years, that’s very meaningful to some patients and caregivers,” Dysken, a professor of psychiatry at the University of Minnesota, said in a Dec. 27 telephone interview.

Dysken, who is a former director of the Geriatric Research, Education and Clinical Center at the Minneapolis VA Health Care System, added that his study “does not address whether vitamin E will prevent Alzheimer’s disease in people who don’t have the diagnosis.”

Veterans Study

The study looked at 613 veterans who were given vitamin E, a combination of vitamin E and Forest Laboratories Inc.’s (FRX) Namenda for moderate to severe Alzheimer’s, Namenda alone or placebo. The vitamin E used in the study was about 20 times greater than the dosage usually found in a multivitamin.

All patients in the trial were on some type of Alzheimer’s medication, such as Eisai Co.’s (4523) Aricept or Johnson & Johnson (JNJ)’s Razadyne. The main outcome was how well patients could perform activities of daily living.

They found that vitamin E slowed the worsening of the disease by 19 percent a year compared with placebo. The research also showed those who took care of patients taking vitamin E were able to spend less time caregiving compared with those taking Namenda alone.

More than 5 million Americans have Alzheimer’s disease, a number projected to triple by 2050, according to the Alzheimer’s Association.

Safety Finding

Vitamin E is naturally found in a variety of foods including wheat germ oil, sunflower seeds, spinach and broccoli. Though some research has linked vitamin E with an increased risk of death, cancer and stroke, no safety issues were seen in the study published today.

Denis Evans, a professor in the Department of Internal Medicine at Rush University Medical Center in Chicago, who wrote an accompanying editorial, said the results of today’s study are “modest” like many trials looking at Alzheimer’s and more research in preventing the disease is needed.

The finding “probably represents something roughly like the ceiling of our current ability to study the disease,” he said in a telephone interview. “That raises the issue of whether we should be looking more at prevention of the disease than treatment of the disease. We should probably emphasize prevention more.”

To contact the reporter on this story: Nicole Ostrow in New York at

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (, the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: